Last reviewed 2026-06-01 · How we verify

Thioderon (MEPITIOSTANE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Thioderon (generic name: MEPITIOSTANE) is a mepitiostane drug. It is currently in Phase 2 development.

Thioderon works by inhibiting an unknown target, but its exact mechanism of action is not well understood.

Thioderon (mepitiostane) is a small molecule drug of the mepitiostane class. Its mechanism of action and target are unknown, and it has not been approved by the FDA for any indications. The commercial status of Thioderon is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety and efficacy. As a result, Thioderon is not currently a viable treatment option.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEPITIOSTANE
Drug class	mepitiostane
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of Thioderon like a key that fits into a lock, but we don't know what the lock is or what it does. When it binds to its target, it can affect various cellular processes, but the specific effects are still unknown. More research is needed to understand how Thioderon works and what it does to the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Thioderon CI brief — competitive landscape report
Thioderon updates RSS · CI watch RSS

Frequently asked questions about Thioderon

What is Thioderon?

Thioderon (MEPITIOSTANE) is a mepitiostane drug.

How does Thioderon work?

Thioderon works by inhibiting an unknown target, but its exact mechanism of action is not well understood.

What is the generic name of Thioderon?

MEPITIOSTANE is the generic (nonproprietary) name of Thioderon.

What drug class is Thioderon in?

Thioderon belongs to the mepitiostane class. See all mepitiostane drugs at /class/mepitiostane.

What development phase is Thioderon in?

Thioderon is in Phase 2.

Drug class: All mepitiostane drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing